Metabolic complications associated with antiretroviral therapy in HIV-infected and HIV-exposed uninfected paediatric patients (Q37676229)

21 August 2017

1 reference

title

Metabolic complications associated with antiretroviral therapy in HIV-infected and HIV-exposed uninfected paediatric patients (English)

1 reference

21 August 2017

0 references

anti-retroviral agent

0 references

author name string

Alessandra Viganò

1

1 reference

21 August 2017

Chiara Cerini

2

1 reference

21 August 2017

Giulia Pattarino

3

1 reference

21 August 2017

Silvia Fasan

4

1 reference

21 August 2017

Gian Vincenzo Zuccotti

5

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

Expert Opinion on Drug Safety

21 August 2017

published in

1 reference

21 August 2017

volume

9

1 reference

21 August 2017

issue

3

1 reference

21 August 2017

page(s)

431-445

1 reference

Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Cancer rates after year 2000 significantly decrease in children with perinatal HIV infection: a study by the Italian Register for HIV Infection in Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Growth of human immunodeficiency virus-infected children receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

A brief overview of mechanisms of mitochondrial toxicity from NRTIs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Serum lactate levels in infants exposed peripartum to antiretroviral agents to prevent mother-to-child transmission of HIV: Agence Nationale de Recherches Sur le SIDA et les Hépatites Virales 1209 study, Abidjan, Ivory Coast

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Risk factors for and outcome of hyperlactatemia in HIV-infected persons: is there a need for routine lactate monitoring?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Management of hyperlactatemia: no need for routine lactate measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Hyperlactatemia in human immunodeficiency virus-infected children receiving antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Lactate levels in children with HIV/AIDS on highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Fatal lactic acidosis during antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Approach to the human immunodeficiency virus-infected patient with lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Treatment options for HIV-associated central fat accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Metabolic complications of antiretroviral therapy in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Metabolic complications of HIV therapy in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Are age references for waist circumference, hip circumference and waist-hip ratio in Dutch children useful in clinical practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Body mass index, waist circumference, and health risk: evidence in support of current National Institutes of Health guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Changes in facial fat in HIV-related lipoatrophy, wasting, and weight gain measured by magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Immunological recovery and metabolic disorders in severe immunodeficiency HIV type 1-infected children on highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Interventions for managing antiretroviral therapy-associated lipoatrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Adherence to Mediterranean diet is favorably associated with metabolic parameters in HIV-positive patients with the highly active antiretroviral therapy-induced metabolic syndrome and lipodystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Metabolic effects of a growth hormone-releasing factor in patients with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Correction of facial lipoatrophy using autologous fat transplants in HIV-infected adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Effects of recombinant growth hormone on visceral fat accumulation: pilot study in human immunodeficiency virus-infected adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Childhood obesity and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Type 2 diabetes in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

The biochemical assessment of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Validation of insulin sensitivity indices from oral glucose tolerance test parameters in obese children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Disorders of glucose metabolism in patients infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

The mechanism of insulin resistance caused by HIV protease inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Metabolic effects of indinavir in healthy HIV-seronegative men

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Insulin resistance in the HIV-infected population: the potential role of mitochondrial dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naive HIV-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Insulin sensitivity and beta-cell function in protease inhibitor-treated and -naive human immunodeficiency virus-infected children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Evaluation of insulin resistance in a cohort of HIV-infected youth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Long-term evaluation of glucose homeostasis in a cohort of HAART-treated HIV-infected children: a longitudinal, observational cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Longitudinal study on pubertal insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Obesity and T2DM in youth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Low prevalence of insulin resistance among HIV-infected children receiving nonnucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Lipid and glucose alterations in HIV-infected children beginning or changing antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Hyperlipidemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Prevalence of elevated cholesterol and associated risk factors among perinatally HIV-infected children (4-19 years old) in Pediatric AIDS Clinical Trials Group 219C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Effects of highly active antiretroviral therapy on paediatric metabolite levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Lipid management in patients who have HIV and are receiving HIV therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Lipid screening and cardiovascular health in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Waist circumference percentiles in nationally representative samples of African-American, European-American, and Mexican-American children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Distribution of Lipoproteins by Age and Gender in Adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Effect of Combination Therapy Including Protease Inhibitors on Mortality among Children and Adolescents Infected with HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903579991

10.1517/14740330903579991

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference